ticlopidine has been researched along with Vascular Calcification in 1 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Vascular Calcification: Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chirumamilla, AP | 1 |
| Maehara, A | 1 |
| Mintz, GS | 1 |
| Mehran, R | 1 |
| Kanwal, S | 1 |
| Weisz, G | 1 |
| Hassanin, A | 1 |
| Hakim, D | 1 |
| Guo, N | 1 |
| Baber, U | 1 |
| Pyo, R | 1 |
| Moses, JW | 1 |
| Fahy, M | 1 |
| Kovacic, JC | 1 |
| Dangas, GD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
1 other study available for ticlopidine and Vascular Calcification
| Article | Year |
|---|---|
High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronar | 2012 |